UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Nanoparticles Enhance Solubility and Neuroprotective Effects of Resveratrol in Demyelinating Disease

Shamsher, Ehtesham; Khan, Reas S; Davis, Benjamin M; Dine, Kimberly; Luong, Vy; Somavarapu, Satyanarayana; Cordeiro, M Francesca; (2023) Nanoparticles Enhance Solubility and Neuroprotective Effects of Resveratrol in Demyelinating Disease. Neurotherapeutics 10.1007/s13311-023-01378-0. (In press).

[thumbnail of Cordeiro_Draft oral resveratrol V5.pdf] Text
Cordeiro_Draft oral resveratrol V5.pdf
Access restricted to UCL open access staff until 10 May 2024.

Download (1MB)

Abstract

Resveratrol is a natural polyphenol which may be useful for treating neurodegenerative diseases such as multiple sclerosis (MS). To date, current immunomodulatory treatments for MS aim to reduce inflammation with limited effects on the neurodegenerative component of this disease. The purpose of the current study is to develop a novel nanoparticle formulation of resveratrol to increase its solubility, and to assess its ability to prevent optic nerve and spinal cord degeneration in an experimental autoimmune encephalomyelitis (EAE) mouse model of MS. Resveratrol nanoparticles (RNs) were made using a thin rehydration technique. EAE mice received a daily oral administration of vehicle, RNs or unconjugated resveratrol for one month. They were assessed daily for clinical signs of paralysis and weekly for their visual acuity with optokinetic responses (OKR). After one month, their spinal cords and optic nerves were stained for inflammation and demyelination and retinal ganglion cells immunostained for Brn3a. RNs were stable for three months. The administration of RNs did not have any effect on clinical manifestation of EAE and did not preserve OKR scores but reduced the intensity of the disease. It did not reduce inflammation and demyelination in the spinal cord and the optic nerve. However, RNs were able to decrease RGC loss compared to the vehicle. Results demonstrate that resveratrol is neuroprotective by reducing RGC loss. Interestingly, neuroprotective effects and decreased disease severity occurred without reduction of inflammation or demyelination, suggesting this therapy may fill an unmet need to limit the neurodegenerative component of MS.

Type: Article
Title: Nanoparticles Enhance Solubility and Neuroprotective Effects of Resveratrol in Demyelinating Disease
Location: United States
DOI: 10.1007/s13311-023-01378-0
Publisher version: https://doi.org/10.1007/s13311-023-01378-0
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: Science & Technology, Life Sciences & Biomedicine, Clinical Neurology, Neurosciences, Pharmacology & Pharmacy, Neurosciences & Neurology, Resveratrol, Neuroprotection, Optic neuritis, Multiple sclerosis, SOLID LIPID NANOPARTICLES, ORAL BIOAVAILABILITY, PLGA NANOPARTICLES, DELIVERY, TPGS
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > Institute of Ophthalmology
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > UCL School of Pharmacy
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > UCL School of Pharmacy > Pharmaceutics
URI: https://discovery.ucl.ac.uk/id/eprint/10173517
Downloads since deposit
2Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item